News | News By Subject | News by Disease News By Date | Search News

Ovarian cancer News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
ImmunoGen (IMGN) CEO Sees Potential in Company’s Lead ADC Product     1/18/2017
Clovis Oncology (CLVS) Stock Hammered After Revealing Mixed Results for Rucaparib     10/10/2016
Clovis Oncology (CLVS) Rockets as FDA Agrees to Priority Review of Rucaparib NDA     8/25/2016
Tesaro (TSRO)'s Phase III NOVA Trial of Niraparib Hits Primary Endpoint; NDA and MAA Planned for Q4 2016     6/29/2016
Oasmia Touts Positive Paclical/Apealea Phase III Data; NDA Being Readied for U.S.     4/27/2016
Array BioPharma (ARRY) to Abandon Testing of Ovarian Cancer Drug     4/1/2016
1,000+ Women are Suing Johnson & Johnson (JNJ) for Allegedly Covering Up Baby Powder Cancer Risk for Decades     4/1/2016
10 Massachusetts Biotechs that Grew Their Headcount by at Least 40% in 2015     3/24/2016
Maharashtra FDA to Test Johnson & Johnson (JNJ) Baby Powder for Cancer-Causing Substances After $75 Million U.S Verdict     3/10/2016
Merck KGaA (MKGAF.PK), Pfizer (PFE) Accelerate Immuno-Oncology Drug Avelumab into Phase III Ovarian and Bladder Cancer Trials     12/22/2015
Top 10 Best-Selling Biotech Drugs     10/2/2015
Celsion (CLSN) Updates Clinical Trial Data and Slashes 20% of Workforce     9/9/2015
ASCO15: Tiny Clovis Oncology (CLVS) Becomes an Even Bigger Takeover Target as Ovarian Cancer Drug Shrunk Tumors in 82% of Women     6/2/2015
ASCO15: BioSpace (DHX)'s Roundup of What You May Have Missed at ASCO So Far     6/1/2015
ASCO15: Analyst Calls ImmunoGen (IMGN)'s Phase I Ovarian Cancer Data "Impressive"     6/1/2015

News from Around the Web
Sought-After Tesaro (TSRO) Sees A $5 Billion Opportunity For Its Cancer Drug     2/17/2017
AstraZeneca PLC (AZN) Is Now A Competitive Threat To Tesaro (TSRO) In Ovarian Cancer Maintenance Therapy     10/26/2016
The Race For PARP, A New Class Of Ovarian Cancer Drugs, Heats Up     10/10/2016
What's Behind FDA's Warning Against Ovarian Cancer Screening Tests?     9/13/2016
Parasite Found In Cat Poop May Actually Help Treat Ovarian Cancer, Dartmouth College Study     7/28/2016
Simplifying Access To Gene Testing For Women With Ovarian Cancer Improves Treatment Choices And Could Save Lives, Institute Of Cancer Research, Study     7/13/2016
Breast, Ovarian Cancer Risk May Have Association With Sense Of Smell, Keck Medicine of USC Study Reveals     10/22/2015
Tea And Citrus Products Could Lower Ovarian Cancer Risk, New University of East Anglia Research Finds     10/29/2014
No Link Found Between Fertility Drugs And Cancers, University of Illinois Study     7/1/2014
Ovarian Cancer Treatment Discovered By St. Joseph's Hospital Researchers     6/23/2014
Irregular Periods: Risk Factor For Ovarian Cancer? Public Health Institute Study     4/10/2014
A Cautionary Perspective on Angelina Jolie's Double Mastectomy     5/15/2013
Ovarian Cancer Vaccine Made From Tumors Yields Responses, University of Pennsylvania Study     4/9/2013
Night Shifts May be Linked to Increased Ovarian Cancer Risk, Fred Hutchinson Cancer Research Center Study     3/15/2013
New Type of Drug Leads to Hope Against Resistant Ovarian Cancer, University of Southern California Study     10/4/2012

Press Releases
OncoMed (OMED) Enrolls First Patient In Phase Ib Clinical Trial Of Its Anti-DLL4/VEGF Bispecific Antibody In Patients With Platinum-Resistant Ovarian Cancer     2/13/2017
Peregrine (PPHM) Release: Recent Publication Highlights Proof-Of-Concept Data Supporting The Diagnostic Potential Of Phosphatidylserine-Positive Exosomes In Ovarian Cancer     2/9/2017
NYU Langone Medical Center Release: Changes In Gene Contribute Independently To Breast And Ovarian Cancer     2/1/2017
ImmunoGen (IMGN) Announces First Patient Dosed In FORWARD I Phase 3 Study Of Mirvetuximab Soravtansine In Platinum-Resistant Ovarian Cancer     1/27/2017
Verastem (VSTM) Announces Dosing Of First Patient In Combination Trial Of Defactinib And Avelumab In Patients With Ovarian Cancer     1/26/2017
Angle Release: Positive Interim Evaluation Of Ovarian Cancer Clinical Studies     1/26/2017
TapImmune (TPIV) Release: Pharma Announces Progress In Its Phase 2 Ovarian Cancer Clinical Trial     1/24/2017
Tesaro (TSRO) Biotech Announces Opening Of Niraparib Expanded Access Program For U.S. Patients With Ovarian Cancer     1/17/2017
TapImmune (TPIV) Release: Pharma Launches Phase 2 Ovarian Cancer Trial In Platinum-Sensitive Patients     1/10/2017
NewVac Reports Primary Endpoint Met In Phase II Clinical Trial Of Quisinostat In Combination With Paclitaxel And Carboplatin In Platinum-Resistant Ovarian Cancer     1/3/2017
ImmunoGen (IMGN) Announces Mirvetuximab Soravtansine Phase 1 Expansion Cohort Results In Platinum-Resistant Ovarian Cancer Published In The Journal Of Clinical Oncology     12/28/2016
Gradalis Inc. Announces A Novel Combination Study Of Vigil EATC In Women With Advanced Ovarian Cancer     12/21/2016
Foundation Medicine, Inc. (FMI) Receives FDA Approval of FoundationFocus CDxBRCA as a Companion Diagnostic for Rubraca (rucaparib) for the Treatment of Women with Ovarian Cancer     12/20/2016
NovoCure Presents Phase 2 Pilot INNOVATE Trial Results Suggesting Tumor Treating Fields Plus Paclitaxel May Be Safe As First-Line Treatment And May Improve Survival Of Patients With Recurrent Ovarian Cancer     12/13/2016
FDA Approves Genentech (RHHBY)’s Avastin (Bevacizumab) Plus Chemotherapy For A Specific Type Of Advanced Ovarian Cancer     12/7/2016

//-->